News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
GeNeuro and Verily Collaborate to Advance Long-COVID Research
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announced a collaboration with Verily, an
Sartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech
STAAR Surgical to Report Third Quarter Results on November 1, 2023
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the third quarter
EQS-News: Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
Humana’s Medicare Advantage Footprint in New Jersey Complete
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding its health plans to Middlesex County, widening the company’s Medicare Advantage footprint to 100% of the state.
For the
Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer® Lens (ICL)
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, is celebrating the 30th anniversary of its proprietary Implantable Collamer®
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
EQS-News: Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing
Charles River Laboratories Schedules Third-Quarter 2023 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2023 financial results on Wednesday, November 8th, before the market opens. A conference call has been
Charles River Laboratories Provides Access to Relevant, Well-Characterized Pediatric PDX Collection for Oncology Research
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the ability to conduct preclinical cancer research using ITCC-P4’s well-characterized collection of 400 annotated
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in
ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid. Novocure will present three new posters
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
Pfizer Inc. (NYSE:PFE) today announced that it has amended its supply agreement with the U.S. government for Paxlovid, the first oral antiviral pill approved by the U.S. Food and Drug
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc